TLV publishes The PPRI Pharma Profile Sweden 2023

The PPRI Pharma Profile Sweden 2023 is an overview of the Swedish system for pricing and reimbursement of pharmaceuticals. It provides an introduction to the legal and political framework governing the Swedish healthcare system and pharmaceutics market. Various statistics are provided to describe the pharmaceutical pricing and reimbursement in Sweden. The out-patient and in-patient sectors are presented separately. Recent, current, and upcoming developments are also described.

The report also highlights a number of key features of the Swedish pharmaceuticals system. Inclusion of pharmaceutics in the subsidy system is dependent on equality, solidarity and cost-effectiveness principles. The subsidy structures caps out-of-pocket expenses for prescription medicines. The Product of the month system enables extensive competition and lowered prices among off-patent pharmaceuticals. Also, while there is collaboration between out- and in-patient pricing and reimbursement, the two operate in two different structures.

The PPRI Pharma Profile Sweden 2023 is made according to the template provided by PPRI, a networking and information-sharing initiative. The PPRI network involves representatives from around 90 institutions and TLV is among them. The PPRI secretariat is hosted at the Pharmacoecoomics Department of the Austrian National Public Health Institute (Gesundheit Österreich GmbH).